Resolving controversies on the path to Alzheimer's therapeutics.
about
Retinoids for treatment of Alzheimer's diseaseThe α-helical content of the transmembrane domain of the British dementia protein-2 (Bri2) determines its processing by signal peptide peptidase-like 2b (SPPL2b)Gpr3 stimulates Aβ production via interactions with APP and β-arrestin2Clec4g (LSECtin) interacts with BACE1 and suppresses Aβ generationAlzheimer disease: new concepts on its neurobiology and the clinical role imaging will playThe amyloid hypothesis of Alzheimer's disease at 25 yearsTesting the right target and right drug at the right stageThe airbag problem-a potential culprit for bench-to-bedside translational efforts: relevance for Alzheimer's diseaseSelf-propagation of pathogenic protein aggregates in neurodegenerative diseasesInconsistencies and controversies surrounding the amyloid hypothesis of Alzheimer's diseaseBlood markers of oxidative stress in Alzheimer's diseaseSystematic, spatial imaging of large multimolecular assemblies and the emerging principles of supramolecular order in biological systems.Alzheimer's-related peptide amyloid-β plays a conserved role in angiogenesisHMGB1, a pathogenic molecule that induces neurite degeneration via TLR4-MARCKS, is a potential therapeutic target for Alzheimer's disease.EPPS rescues hippocampus-dependent cognitive deficits in APP/PS1 mice by disaggregation of amyloid-β oligomers and plaquesLysosome and calcium dysregulation in Alzheimer's disease: partners in crimePotential Links between Impaired One-Carbon Metabolism Due to Polymorphisms, Inadequate B-Vitamin Status, and the Development of Alzheimer's DiseaseSynaptopathies: synaptic dysfunction in neurological disorders - A review from students to studentsWhat can triumphs and tribulations from drug research in Alzheimer's disease tell us about the development of psychotropic drugs in general?APOE-modulated Aβ-induced neuroinflammation in Alzheimer's disease: current landscape, novel data, and future perspectiveBezafibrate administration improves behavioral deficits and tau pathology in P301S miceBrain intraventricular injection of amyloid-β in zebrafish embryo impairs cognition and increases tau phosphorylation, effects reversed by lithiumNanoscale Synaptic Membrane Mimetic Allows Unbiased High Throughput Screen That Targets Binding Sites for Alzheimer's-Associated Aβ Oligomers.Pancortins interact with amyloid precursor protein and modulate cortical cell migrationAmyloid-β peptide-specific DARPins as a novel class of potential therapeutics for Alzheimer diseaseAnle138b: a novel oligomer modulator for disease-modifying therapy of neurodegenerative diseases such as prion and Parkinson's disease.Suppression of eIF2α kinases alleviates Alzheimer's disease-related plasticity and memory deficits.A paired RNAi and RabGAP overexpression screen identifies Rab11 as a regulator of β-amyloid production.Small molecule p75NTR ligands reduce pathological phosphorylation and misfolding of tau, inflammatory changes, cholinergic degeneration, and cognitive deficits in AβPP(L/S) transgenic mice.Alzheimer's disease: pathophysiology and applications of magnetic nanoparticles as MRI theranostic agents.'Shooting at the sun god Apollo': the Apollonian-Dionysian balance of the TimeSlips Storytelling Project.Recent Progress in Alzheimer's Disease Research, Part 3: Diagnosis and Treatment.Biology and genetics of prions causing neurodegenerationPAK inactivation impairs social recognition in 3xTg-AD Mice without increasing brain deposition of tau and AβExosome reduction in vivo is associated with lower amyloid plaque load in the 5XFAD mouse model of Alzheimer's disease.1α,25-dihydroxyvitamin D3 and resolvin D1 retune the balance between amyloid-β phagocytosis and inflammation in Alzheimer's disease patientsApolipoprotein E epsilon4 does not modulate amyloid-β-associated neurodegeneration in preclinical Alzheimer disease.BACE1 is necessary for experience-dependent homeostatic synaptic plasticity in visual cortexHuman APOE4 increases microglia reactivity at Aβ plaques in a mouse model of Aβ deposition.An expanded role for neuroimaging in the evaluation of memory impairment.
P2860
Q22252919-78C43EDE-CD17-4DE0-B5E1-A3E800D2F1E2Q24300479-36602EEB-2508-4452-8701-3C065A27C767Q24337284-3D34971E-E2BC-414F-8DDD-721011B0A537Q24337410-CC982D04-0B6E-4886-9786-4A059663E4D0Q24594531-B9A7F9C9-F558-4043-9222-0B923886BE00Q26749528-A7CE5181-312D-41A7-83FC-2DC260F15661Q26864854-25A9DA39-22CD-4A9A-A783-F3A58168AAE4Q26991654-DE7E15B0-281F-4942-AED5-BF49D6CB241CQ26996441-3C47092A-5B93-4B5A-B6D1-A2774061EDD2Q27003841-8FC4FC00-5BB6-4079-BE71-F805775BD99FQ27021625-6FE119FC-37A3-41DE-8BCF-4FB91EA7E8C8Q27026607-D9C358AB-C030-4430-8F62-19B237E37A10Q27300765-3EBFA201-C325-488B-A92B-40C43F6FB4FEQ27315985-5B51909F-2AA5-4DF9-A720-A9652363FB4AQ27316634-1F18A642-92D7-437E-9FE6-46621B37E051Q27693256-C2BFD594-A518-449C-8C3F-112A4AE5079EQ28068353-33562E21-5F89-4ED6-B43D-0587071176FEQ28077671-9B375197-2C73-4221-AFD3-919CA5B5F9EEQ28083481-2678B7B0-2F9B-486E-B422-53B14C5A7CBEQ28085213-04244586-77DC-46A6-BFE0-77A11B530BF2Q28273620-CEFEA35B-16B8-4976-BD7B-B5C4F0491FDCQ28542815-DF87DE8F-A888-489B-AA54-4B1E2CD039C3Q28546877-A53B29EC-BF69-4865-BD54-418D690CC7EBQ28593653-2E507FB5-E333-4015-A3FB-2FAD9F052D7FQ28655482-F9062E27-A04B-408F-9EB4-6FBACA90AA0CQ30540027-A45AC14E-534B-4473-8C5A-3A9505B610B5Q30543820-BFE1486B-B30C-4E86-B917-804F100C7752Q30577278-01CD911C-8AFB-45AB-B5E3-8C0801E4C9E0Q30611779-66578719-4663-4F4C-AA87-9D86B73A7714Q30666219-4D0B6D2D-802F-44F3-BA87-D5B550A0AB75Q33458144-43C21D44-26A7-4BC6-9918-9828166D7C04Q33556068-A8A892B0-5575-4B01-B7B5-F938D457999BQ33567229-D7DBA450-8A36-4BAE-B606-477E32BAD1E8Q33605706-158AD4E1-BED1-4CF5-B391-D7C2BC31C4F2Q33670207-9F57D878-E6F0-4D0A-B1BB-A5BB6D87C88FQ33691958-8F7651C4-20FB-4722-98E5-58CE2C79A7F1Q33699415-C664E901-B427-45A7-BD03-AF9C2C83BA94Q33740069-4F86A0B6-C4E1-4202-9464-43E2F534FEB1Q33830137-88435431-7A85-4641-8AF6-8DF168CABCE0Q33830698-DA105FF4-D40B-48C3-A76F-DF46F36E742F
P2860
Resolving controversies on the path to Alzheimer's therapeutics.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
Resolving controversies on the path to Alzheimer's therapeutics.
@en
Resolving controversies on the path to Alzheimer's therapeutics.
@nl
type
label
Resolving controversies on the path to Alzheimer's therapeutics.
@en
Resolving controversies on the path to Alzheimer's therapeutics.
@nl
prefLabel
Resolving controversies on the path to Alzheimer's therapeutics.
@en
Resolving controversies on the path to Alzheimer's therapeutics.
@nl
P356
P1433
P1476
Resolving controversies on the path to Alzheimer's therapeutics.
@en
P2093
Dennis J Selkoe
P2888
P304
P356
10.1038/NM.2460
P407
P577
2011-09-07T00:00:00Z